<DOC>
	<DOCNO>NCT00005593</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase I trial study effectiveness fludarabine , carboplatin , topotecan treating patient relapse refractory acute leukemia advance myelodysplastic syndrome .</brief_summary>
	<brief_title>Fludarabine , Carboplatin , Topotecan Treating Patients With Relapsed/Refractory Acute Leukemia Advanced Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose topotecan administer carboplatin fludarabine patient refractory relapse acute leukemia advance myelodysplastic syndrome . II . Determine treatment relate dose limit toxicity regimen patient . III . Determine antileukemia activity regimen patient . IV . Correlate treatment related toxicity steady state level topotecan patient . OUTLINE : This dose escalation study topotecan . Patients receive carboplatin IV continuously fludarabine IV 30 minute day 1-5 , topotecan IV continuously day 6-8 . Patients residual leukemia bone marrow day 15 may receive second induction course . Patients achieve partial complete remission 1-2 induction course receive 1 consolidation course fludarabine , carboplatin , topotecan begin 4-8 week recovery induction therapy . Cohorts 3-6 patient receive escalate dos topotecan maximum tolerate dose ( MTD ) determine . The first 3 patient receive topotecan . The MTD define dose 2 6 patient experience dose limit toxicity . Patients follow monthly 6 month . PROJECTED ACCRUAL : A total 6-15 patient accrue study within 15-21 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one following : Acute myelogenous leukemia ( M0M7 ) M3 must receive tretinoin part induction salvage chemotherapy No great 2 prior intensive induction regimen Acute lymphocytic leukemia ( L1 L2 ) first second relapse Circulating blast blood great 5 % blast bone marrow No great 2 prior intensive induction regimens Chronic myelogenous leukemia myeloid lymphoid blast crisis Initial diagnosis OR No great 2 prior intensive induction regimen Acute myelogenous leukemia secondary prior myelodysplastic syndrome prior cytotoxic therapy No great 2 prior intensive induction regimens Myelodysplastic syndrome ( must neutropenic ( absolute neutrophil count le 500/mm3 ) platelet red cell transfusion dependent ) Refractory anemia excess blast ( RAEB ) OR RAEB transformation OR Chronic myelomonocytic leukemia Relapse great 3 month since prior autologous stem cell transplant allow No relapse allogeneic bone marrow transplant No active CNS leukemia PATIENT CHARACTERISTICS : Age : 12 Performance status : ECOG 03 Life expectancy : At least 4 week Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 2.0 mg/dL AST ALT less 3 time upper limit normal Renal : Creatinine clearance least 50 mL/min Cardiovascular : No symptomatic cardiac disease No active ischemic heart disease No poorly control congestive heart failure No myocardial infarction within past 6 month Cardiac ejection fraction least 40 % Pulmonary : No symptomatic pulmonary disease No symptomatic restrictive obstructive lung disease Other : Not pregnant nursing Fertile patient must use effective contraception No active infection , unless receive antibiotic clinically stable Fever cause tumor allow HIV negative No active malignant disease Curatively treat prior malignancy allow No severe neurologic disease PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 5 day since prior hematopoietic growth factor Chemotherapy : See Disease Characteristics At least 24 hour since prior hydroxyurea At least 2 week since prior cytotoxic anticancer therapy Prior carboplatin , fludarabine , topotecan allow Endocrine therapy : Concurrent corticosteroid allow Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>L1 childhood acute lymphoblastic leukemia</keyword>
	<keyword>L2 childhood acute lymphoblastic leukemia</keyword>
	<keyword>L1 adult acute lymphoblastic leukemia</keyword>
	<keyword>L2 adult acute lymphoblastic leukemia</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute monoblastic leukemia ( M5a )</keyword>
	<keyword>childhood acute monocytic leukemia ( M5b )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>